Eli Lilly (LLY)

Midwest to list at 10 a.m. with GMP indicating a premium of ₹111

These exchange-traded funds could be great complementary additions to your portfolio.

The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.

Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests.

Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending.

Since April 2025, Eli Lilly has been in a holding pattern, posting a small loss of 2.2% while floating around $811. The stock also fell short of the S&P 500’s 24.7% gain during that period.

The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift towards personalized medicine. Artificial intelligence (AI) stands at the forefront of this revolution, offering unprecedented capabilities to overcome long-standing challenges and accelerate the delivery of tailored, effective treatments. [...]

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,

Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move orchestrated by its top investor, the non-profit Novo Nordisk Foundation. The shake-up, which will see seven independent board members, including the chairman, step

Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager

The rapid growth rates of recent years aren't guaranteed to continue.

Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains.

Don't try to catch a falling surgical knife.

The tides continue to change in Eli Lilly's favor in the GLP-1 space.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

As the financial markets gear up for the week commencing Monday, October 20, 2025, investors are keenly attuned to the insights of CNBC's Jim Cramer, a vocal and influential voice in the stock market. While a precise, real-time "Top 10" list from Cramer for this specific Monday is not publicly

The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.

These companies are jockeying for position in a potential $150 billion market opportunity.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.